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Abstract
Background: Nuclear factor-κB (NF-κB) is constitutively activated in many cancers and plays a key role in promoting 
cell proliferation, survival, and invasion. Our understanding of NF-κB signaling in thyroid cancer, however, is limited. In 
this study, we have investigated the role of NF-κB signaling in thyroid cancer cell proliferation, invasion, and apoptosis 
using selective genetic inhibition of NF-κB in advanced thyroid cancer cell lines.
Results: Three pharmacologic inhibitors of NF-κB differentially inhibited growth in a panel of advanced thyroid cancer 
cell lines, suggesting that these NF-κB inhibitors may have off-target effects. We therefore used a selective genetic 
approach to inhibit NF-κB signaling by overexpression of a dominant-negative IκBα (mIκBα). These studies revealed 
decreased cell growth in only one of five thyroid cancer cell lines (8505C), which occurred through a block in the S-G2/
M transition. Resistance to TNFα-induced apoptosis was observed in all cell lines, likely through an NF-κB-dependent 
mechanism. Inhibition of NF-κB by mIκBα sensitized a subset of cell lines to TNFα-induced apoptosis. Sensitive cell lines 
displayed sustained activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway, 
defining a potential mechanism of response. Finally, NF-κB inhibition by mIκBα expression differentially reduced 
thyroid cancer cell invasion in these thyroid cancer cell lines. Sensitive cell lines demonstrated approximately a two-
fold decrease in invasion, which was associated with differential expression of MMP-13. MMP-9 was reduced by mIκBα 
expression in all cell lines tested.
Conclusions: These data indicate that selective inhibition of NF-κB represents an attractive therapeutic target for the 
treatment of advanced thyroid. However, it is apparent that global regulation of thyroid cancer cell growth and 
invasion is not achieved by NF-κB signaling alone. Instead, our findings suggest that other important molecular 
processes play a critical role in defining the extent of NF-κB function within cancer cells.
Background
Thyroid cancer is the most common endocrine malig-
nancy [1]. Fortunately, a majority of patients are managed
successfully with a combination of radioiodine and
levothyroxine treatment following complete thyroidec-
tomy. However, a subset of patients with advanced/dedif-
ferentiated cancer have radioiodine-refractory disease
with associated morbidity and mortality [2]. Given the
high frequency of activating mutations in the mitogen-
activated protein kinase (MAPK) pathway achieved by
rearrangements associated with the RET tyrosine kinase
and activating point mutations in RAS and BRAF [3],
therapies targeting this pathway have been an area of
active investigation [4]. Unfortunately, results from clini-
cal studies regarding the overall efficacy of these thera-
pies have been modest [5]. Clearly, there remains a need
for a better understanding of the molecular events
involved in thyroid cancer initiation and progression to
aid in the identification of novel therapeutic targets.
The nuclear factor-κB (NF-κB) family of transcription
factors is comprised of RelA (p65), RelB, c-REL, NF-κB1/
p50, and NF-κB2/p52, each of which is characterized by a
Rel homology domain, which facilitates DNA-binding,
homo- or heterodimerization of NF-κB family members,
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Page 2 of 13and interaction with inhibitory IκB proteins. A role for
NF-κB in oncogenic progression has been described in a
number of lymphoid malignancies and carcinomas,
including thyroid, ovarian, breast, and hepatocellular car-
cinomas [6]. Moreover, constitutive activation of NF-κB
in tumors has been attributed to both excessive, chronic
inflammation and activation by oncoproteins, as
observed in hepatitis-induced hepatocellular carcinoma
and melanoma, respectively [7,8]. NF-κB activation has
also been implicated in acquired resistance to chemo-
therapy and radiation [9,10]. The end-product of NF-κB
activation in cancer is believed to entail enhanced cell
proliferation and invasion, as well as resistance to apopto-
sis induced by tumor surveillance mechanisms and vari-
ous therapeutic modalities [10,11].
While the two primary modes of NF-κB activation are
similar in that they culminate in NF-κB-dependent gene
regulation through nuclear translocation of NF-κB dim-
ers, the pathways are distinguished by the differential
requirement of the trimeric IκB kinase (IKK) complex,
which is composed of two kinase subunits, IKKα and
IKKβ, and a regulatory, scaffolding subunit IKKγ. The
classical pathway of activation requires phosphorylation
of IκB proteins by the trimeric IKK complex, resulting in
proteasome-dependent degradation of the inhibitory
proteins and nuclear translocation of the classical p50/
p65 heterodimer. The alternative pathway involves cleav-
age of the NF-κB2 precursor protein into the functional
p52 subunit, which may then complex with RelB. This
pathway is dependent on phosphorylation of the NF-κB2
precursor by IKKα dimers [12].
To date, several studies have employed the use of phar-
macologic inhibitors of NF-κB to establish a role for NF-
κB in thyroid cancer cell growth and invasion [13-17].
However, these results should be interpreted with caution
given the potential for off-target effects of many of these
drugs. In this report, we used a selective genetic inhibitor
of NF-κB (mIκBα) in a panel of authenticated thyroid
cancer cell lines [18]. We demonstrate that inhibition of
NF-κB decreases thyroid cancer cell proliferation and
invasion, while promoting TNFα-induced apoptosis.
These findings are observed in only a subset of thyroid
cancer cell lines and appear to be associated with distinct
regulatory mechanisms.
Results
Inhibition of Thyroid Cancer Cell Growth by Pharmacologic 
Inhibition of NF-κB
Pharmacologic inhibitors of NF-κB have been widely
used to investigate the functional consequences of consti-
tutive NF-κB activation in cancer. Many of these inhibi-
tors prevent phosphorylation and degradation of IκBα by
blocking IKK complex activity [19]. We initially tested
three NF-κB inhibitors, Bay 11-7082 (1 μM), IKK Inhibi-
tor VII (1 μM), and CDDO-Me (0.25 μM), to investigate
the role of NF-κB in thyroid cancer cell growth. The con-
centrations used in these experiments were based on
studies using these compounds to document NF-κB-
dependent effects on cell growth [20-22]. Each com-
pound demonstrated inhibition of IKKβ activity by block-
ing TNFα-induced nuclear localization of p65 in a dose-
dependent manner (data not shown).
A panel of papillary thyroid cancer (PTC) (BCPAP,
TPC1) and anaplastic thyroid cancer (ATC) (SW1736,
C643) cell lines were used. These cell lines harbour differ-
ent activating mutations in the MAPK pathway, including
the HRAS G13R mutation (C643), the BRAF V600E
mutation (BCPAP, SW1736), and the RET/PTC1 rear-
rangement (TPC1) [18]. Treatment with CDDO-Me, Bay
11-7082, and IKK Inhibitor VII inhibited growth in all cell
lines. Interestingly, the effects of the inhibitors on TPC1
(RET/PTC1) and C643 (HRAS) cells were quite variable,
while the cells harbouring a BRAF V600E mutation
(BCPAP and SW1736) displayed similar degrees of sensi-
tivity to each of the inhibitors (Figure 1). The variable
growth inhibition of these cell lines in response to treat-
ment with three NF-κB inhibitors suggests that these
inhibitors may exert their growth inhibitory effects
through off-target mechanisms that are independent of
NF-κB signaling.
Inhibition of NF-κB by Adenoviral-mediated 
Overexpression of mIκBα
Based on the variable growth inhibition by different phar-
macologic inhibitors of NF-κB, a selective genetic
approach to inhibit NF-κB signaling was used. Specifi-
cally, expression of a dominant-negative IκBα (mIκBα)
[23,24], which is resistant to IKK-induced phosphoryla-
tion and proteasomal degradation, was carried out by
adenoviral transduction [25]. This results in cytoplasmic
sequestration and transcriptional inactivation of the NF-
κB family of proteins. For these studies, we added the
8505C ATC cell line, which is characterized by the BRAF
V600E mutation [18]. Adenoviral-mediated expression of
mIκBα was assessed by Western blot analysis following
transduction of thyroid cancer cell lines with a multiplic-
ity of infection (MOI) ranging from 5-250 (Figure 2A).
Expression levels of mIκBα varied substantially across the
five cell lines tested, likely because of the efficiency of
viral transduction. Indeed, a direct correlation between
transduction efficiency, which was assessed by adenovi-
ral-mediated expression of GFP, and mIκBα expression
was observed (Figure 2A and data not shown).
The five thyroid cancer cell lines demonstrated differ-
ent basal levels of NF-κB transcriptional activity as deter-
mined by an NF-κB-responsive luciferase reporter, with
the BCPAP and 8505C cell lines exhibiting the highest
levels of NF-κB activity (Figure 2B). Basal NF-κB activity
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Page 3 of 13did not correlate with tumor type (ATC vs. PTC). Figure
2C shows that NF-κB transcriptional activity could be
inhibited by greater than 90% in each of the five cell lines.
The degree of inhibition at a given MOI correlated with
mIκBα protein expression in each of the cell lines. Impor-
tantly, transduction of cells with Ad-GFP at the same
MOI had no effect on NF-κB transcriptional activity (data
not shown). These results demonstrate effective inhibi-
tion of constitutive NF-κB activity in our panel of 5 thy-
roid cancer cell lines.
The Role of NF-κB in Thyroid Cancer Cell Growth
We next investigated the role of NF-κB in thyroid cancer
cell proliferation and survival. Thyroid cancer cells were
transduced with either Ad-mIκBα or Ad-GFP at an MOI
of 50 or 200, and growth was assessed after 5 days by
automated viable cell counting. Transduction with con-
trol Ad-GFP was performed to monitor transduction effi-
ciency and control for the effects of adenoviral
transduction on cell growth. Inhibition of NF-κB by
mIκBα expression did not decrease thyroid cancer cell
proliferation or survival in four of the five cell lines tested
(Figure 3), even under conditions of serum starvation
(0.5% FBS) (data not shown). However, the 8505C cell line
showed a 42% decrease in cell growth in response to NF-
κB inhibition when transduced with an MOI of 50. 8505C
cell growth was inhibited with an MOI as low as 5 (36%
inhibition; data not shown), confirming that NF-κB-
dependent regulation of 8505C cell growth was not due
to higher levels of mIκBα expression (Figure 2A).
To determine the mechanisms governing growth inhi-
bition by mIκBα in the 8505C cell line, measures of apop-
tosis and cell cycle analysis were performed. Cleaved poly
(ADP-ribose) polymerase (PARP), a measure of apopto-
sis, was undetectable by Western blot analysis, suggesting
that NF-κB inhibition does not induce apoptosis (data not
shown). However, flow cytometry revealed a significant
increase in the number of cells in S-phase following
mIκBα expression. This finding corresponded with a 28%
decrease in the number of mIκBα-expressing cells in G2/
M, indicating a block in the S-phase to G2/M transition
(Figure 4A). Western blot analysis (Figure 4B) of cell cycle
regulatory proteins demonstrated no regulation of cyclin
A protein levels and only a small decrease in phospho-
Figure 1 Three Pharmacologic Inhibitors of NF-κB Differentially Decrease Growth of Thyroid Cancer Cell Lines. BCPAP, SW1736, TPC1, and 
C643 cells were treated with vehicle (DMSO), (A) CDDO-Me (0.25 M), (B) Bay-11-7082 (1 M), or (C) IKK Inhibitor VII (1 M) for 5 days. Effect of treatment 
on proliferation and survival was determined by automated viable cell counting. Data is represented as percent viable cells/mL compared to vehicle 
control (normalized to 100%), which is denoted by the dashed line. Mean ± S.E.M. of 3 independent experiments performed in duplicate is reported. 
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Page 4 of 13cdc2 levels in response to NF-κB inhibition. Notably, NF-
κB inhibition resulted in an increase in p21 levels and
decrease in the levels of cyclin B1, suggesting that the
transition from S-phase to G2/M in 8505C cells is medi-
ated by NF-κB-dependent regulation of cyclin B1 and
p21. Based on the profound growth arrest observed in
8505C cells by NF-κB inhibition, this cell line was not
used in subsequent studies of TNFα-induced apoptosis or
invasion.
The Role of NF-κB in Resistance to TNFα-induced Apoptosis
TNFα signaling is responsible for activation of numerous
pro-apoptotic pathways, which can be opposed by pro-
survival NF-κB signaling through activation of the IKK
complex [26]. Figure 5A (GFP) shows that thyroid cancer
cell lines are resistant to TNFα-induced apoptosis, as cells
transduced with control Ad-GFP displayed no significant
decrease in cell viability following treatment with TNFα.
We also observed that TNFα treatment resulted in the
nuclear accumulation of p65, suggesting that increased
NF-κB signaling promotes resistance to TNFα-induced
apoptosis (Figure 5B; GFP). We therefore predicted that
inhibition of TNFα-induced nuclear translocation of p65
would sensitize thyroid cancer cell lines to TNFα-
induced apoptosis. As expected, expression of mIκBα
greatly reduced nuclear translocation of p65 due to TNFα
treatment, and lower levels of basal nuclear p65 were also
observed in SW1736, TPC1, and C643 cells transduced
with Ad-mIκBα when compared to control (Figure 5B).
Interestingly, TNFα treatment in combination with NF-
κB inhibition decreased cell viability in only two of the
cancer cell lines (SW1736 and TPC1) (Figure 5A).
Accordingly, levels of cleaved PARP, a marker of apopto-
sis, were increased after treatment with TNFα in SW1736
and TPC1 cells expressing mIκBα but not in cells express-
ing control GFP (Figure 5C). Cleaved PARP was not
Figure 2 Adenoviral-mediated Expression of mIκBα Blocks NF-κB Transcriptional Activity. (A) BCPAP, SW1736, 8505C, TPC1, and C643 cells 
were transduced with Ad-mIκBα at an MOI of 0, 5, 25, 50, 100, and 250. After 48 hours, whole cell lysates were prepared, and expression levels of mIκBα 
were assessed by Western blot analysis. α-tubulin was used as a loading control. (B) Cells were transfected with an NF-κB-responsive luciferase report-
er and actin-β-gal expression vector to control for transfection efficiency. Cell lysates were prepared 24 hours after transfection, after which luciferase 
and β-gal activities were assayed. Data is represented as NF-κB activity [luciferase activity/β-gal activity; relative light units (RLU)]. Mean ± S.E.M. of 3 
independent experiments performed is reported. (C) Cells were transduced with Ad-mIκBα at an MOI of 0, 5, 25, 50, 100, and 250. After 24 hours, cells 
were then transfected with an NF-κB-responsive luciferase reporter and actin-β-gal expression vector to control for transfection efficiency. Cell lysates 
were prepared 24 hours after transfection, after which luciferase and β-gal activities were assayed. Data is represented as fold NF-κB activity where the 
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Page 5 of 13detected in TNFα/mIκBα resistant BCPAP or C643 cells
(data not shown).
To investigate the mechanisms by which only a subset
of cell lines are sensitized to the combined pro-apoptotic
effects of TNFα treatment and NF-κB inhibition, we
examined activation of the pro-apoptotic JNK/SAPK
pathway. Activation of the JNK pathway was assessed by
Western blot analysis with an antibody specific to the
activated, phosphorylated (Thr183/Tyr185) forms of
JNK1/2. Transient activation of JNK/SAPK pathway in
control GFP-transduced cells was only observed in the
TPC1 cell line (Figure 6). Interestingly, sustained activa-
tion of the JNK pathway was observed in response to
TNFα treatment only in mIκBα-expressing cell lines
(SW1736, TPC1) that were sensitive to the pro-apoptotic
effects of combined TNFα treatment and genetic inhibi-
tion of NF-κB signaling (Figure 5A and 6).
The Role of NF-κB in Thyroid Cancer Cell Invasion
An understanding of the role of NF-κB signaling in regu-
lation of thyroid cancer cell invasion is particularly rele-
vant given the nature of the disease and the mortality
associated with locally invasive and metastatic tumors.
Therefore, we assessed the role of NF-κB in thyroid can-
cer cell invasion using Matrigel-coated transwell assays.
In these studies, cells (BCPAP, SW1736, TPC1, C643)
were transduced with either Ad-GFP or Ad-mIκBα and
allowed to invade for 24 hours. Control-transduced C643
cells were the most invasive (~450 cells/field), while
TPC1 cells were the least invasive (~150 cells/field).
SW1736 and BCPAP cells were moderately invasive
(~300 cells/field) (data not shown). Invasion by the
SW1736 and TPC1 cell lines was significantly inhibited
(46% and 44%, respectively) by mIκBα expression, while
BCPAP and C643 cells were resistant (Figure 7).
To investigate the mechanism by which NF-κB regu-
lates thyroid cancer cell invasion, we performed quantita-
tive RT-PCR to examine the NF-κB-dependent regulation
of the matrix metalloproteinase (MMP) -2, MMP-9, and
MMP-13 (Figure 8). Figure 8 shows that transcript levels
of MMP-2 and MMP-13 were not significantly affected
by mIκBα expression after 48 hours. Interestingly, both
resistant cell lines (BCPAP, C643) expressed basal MMP-
13 transcripts levels that were at least two-fold higher
(p<0.05) than either of the sensitive cell lines, while
MMP-2 levels were similar across all cell lines (Figure 8A,
B). Figure 8C shows that MMP-9 transcript levels were
decreased significantly by NF-κB inhibition in both the
resistant [BCPAP (~2.5 fold), C643 (~7 fold)] and sensi-
tive [SW1736 (~4.5 fold), TPC1 (~3 fold)] cell lines.
Discussion
In this report, we have used a selective genetic inhibitor
of NF-κB signaling to determine the effects of this path-
way on proliferation, apoptosis, and invasion in a panel of
ATC and PTC thyroid cancer cell lines. Our data indicate
that NF-κB does not have one common role in the regula-
tion of proliferation, apoptosis, or invasion in advanced
thyroid cancer and that sensitivity to NF-κB inhibition
does not correlate with baseline levels of NF-κB tran-
scriptional activity. Instead, we have demonstrated that
some cancer cells depend on NF-κB signaling for prolifer-
ation (8505C), while others require it for invasion and
resistance to TNFα-induced apoptosis (TPC1, SW1736).
Furthermore, some cell lines are not dependent on NF-κB
signaling for these basic cancer properties (BCPAP,
C643).
The hallmarks of cancer include self-sufficiency in
growth signals, resistance to anti-growth signals, evasion
of apoptosis, unlimited replication potential, sustained
angiogenesis, and acquisition of metastatic/invasive
potential [27]. Activation of NF-κB signaling in cancer is
a critical mediator in the majority, if not all, of these pro-
cesses [11]. This theory has led to numerous studies
aimed at identifying a link between NF-κB signaling and
thyroid cancer growth and progression. Using the NF-κB
inhibitor DHMEQ, Yamashita and colleagues showed
decreased tumor growth, cancer cell invasion, increased
apoptosis, as well as TNFα- and taxane-induced apopto-
sis in a single ATC cell line [13,14]. Liu and Xing demon-
strated synergistic inhibition of cell proliferation in a
panel of thyroid cancer cell lines when combining a
Figure 3 Mutant IκBα Expression Inhibits Growth of the 8505C 
Anaplastic Thyroid Cancer Cell Line. BCPAP, SW1736, 8505C, TPC1, 
and C643 cells were transduced with either Ad-GFP (as an appropriate 
control) or Ad-mIκBα at the indicated MOI. Cells were harvested for au-
tomated viable cell counting after 5 days. Data is represented as per-
cent viable cells/mL compared to Ad-GFP control (normalized to 
100%), which is denoted by the dashed line. Mean ± S.E.M. of 3 inde-
pendent experiments is reported. [p < 0.05 (*); p < 0.01 (**); p < 0.001 
(***)].
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Page 6 of 13MEK1/2 inhibitor with PS1145, an IKK complex inhibitor
[17]. Another study by Zhu and colleagues showed that a
small molecule triptolide inhibited angiogenesis, inva-
sion, and proliferation in a single ATC cell line and fur-
ther suggested that this was associated with inhibition of
NF-κB transcriptional activity [15]. The primary genetic
study linking NF-κB to thyroid cancer was performed by
Pacifico and colleagues via stable overexpression of
mIκBα in the FRO ATC cell line. In doing so, they showed
that NF-κB promotes in vivo tumor formation, growth in
soft-agar, and resistance to chemotherapy-induced apop-
tosis [28]. Our studies have extended the use of a genetic
model to identify a role for NF-κB signaling in a panel of
authenticated thyroid cancer cell lines, and in doing so,
we have advanced knowledge of the role of NF-κB in thy-
roid cancer proliferation, apoptosis, and invasion.
Previous studies in cancer models, including thyroid
cancer, have cited a role for NF-κB in malignant cell pro-
liferation by transcriptional regulation of cyclin D1,
CDK2, cyclin E and c-Myc [11]. Using a selective genetic
model, however, we have shown that NF-κB regulates
cancer cell proliferation in only one of five cell lines tested
(Figure 3). Cell cycle arrest was induced in the 8505C
ATC cell line by blocking the transition from S-phase to
G2/M (Figure 4A), representing a novel mechanism for
the regulation of thyroid cancer cell proliferation by NF-
κB. While cyclin A is critical for progression through S-
phase [29], protein levels were not affected by NF-κB
inhibition (Figure 4B). Similarly, dephosphorylation of
cdc2 at Tyr 15, which is predicted upon entry into G2/M
[29], was observed (Figure 4B). However, protein levels of
cyclin B1, which is necessary for the entry into and pro-
gression through G2-phase and mitosis [29], were
decreased following NF-κB inhibition (Figure 4B). Inter-
estingly, this finding was associated with increased levels
of the cyclin-dependent kinase inhibitor, p21 (Figure 4B).
Indeed, increased levels of p21 have been shown to medi-
ate p53-induced cell cycle arrest in response to genotoxic
stress by down-regulation of cyclin B1 expression [30].
NF-κB signaling has also been shown to inhibit cell cycle
arrest by decreasing p21 levels in osteoblasts [31] and
normal epithelial cells in a manner dependent on the
Figure 4 Transition from S-phase to G2/M is Blocked in 8505C Cells in Response to NF-κB Inhibition. (A) 8505C cells were transduced with ei-
ther Ad-GFP vs. Ad-mIκBα at an MOI of 25. After 48 hours, cells were harvested, and permeabilized. DNA was stained with a saponin/propidium iodide 
solution and subjected to cell cycle analysis by flow cytometry. Data is represented as relative cell number (%) in G1, S, or G2/M. Mean ± S.E.M. of 2 
independent experiments performed in duplicate is reported. [p < 0.05 (*); p < 0.01 (**); p < 0.001 (***)] (B) 8505C cells were transduced with either 
Ad-GFP or Ad-mIκBα at an MOI of 25. Whole-cell lysates were prepared 24 and 48 hours post-transduction, and levels of cyclin A, cdc2, phospho-cdc2, 
cyclin B1, and p21 were assessed by Western blot analysis. α-tubulin was used as a loading control.
GFP GFPmIB mIB
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Page 7 of 13phosphatidylinositol-3-kinase (PI3K) pathway [32]. Simi-
lar observations have been made in prostate cancer cells
[33], thereby providing substantial evidence for a mecha-
nism by which decreased NF-κB signaling in the 8505C
cell line leads to decreased cyclin B1 expression in a p21-
dependent manner.
The ability of NF-κB signaling to deregulate pro-
grammed cell death by apoptosis is a major mechanism
by which NF-κB exerts its pro-tumorigenic functions.
This effect is often achieved by transcriptional regulation
of anti-apoptotic genes, including Bcl-2 family members
[11,13,34]. Starenki and colleagues demonstrated that
inhibition of NF-κB by DHMEQ in thyroid cancer cells
induced spontaneous apoptosis through down-regulation
of cIAP-1, cIAP-2, and XIAP [13]. However, our studies
indicate that genetic inhibition of NF-κB in a panel of
thyroid cancer cell lines does not induce spontaneous
apoptosis even under conditions of serum-starvation
(Figure 3 and data not shown). Pacifico and colleagues
obtained similar results when stably overexpressing
mIκBα in the FRO ATC cell line [28].
NF-κB signaling is critical for blocking apoptosis fol-
lowing ligand binding by members of the tumor necrosis
factor receptor (TNFR) superfamily. Members of this
family induce activation of the extrinsic apoptosis path-
way by a cytoplasmic death domain. These receptors
include the classical receptor TNFR1, which binds the
inflammatory cytokine TNFα, as well as Fas, TNF-related
apoptosis-inducing ligand (TRAIL)-receptor 1, and
TRAIL-R2 [35,36]. Pro-apoptotic effects of TNFR1 acti-
Figure 5 NF-κB Inhibition Differentially Sensitizes Thyroid Cancer Cell Lines to TNFα-induced Apoptosis. (A) BCPAP, SW1736, TPC1, and C643 
cells were transduced with either Ad-GFP or Ad-mIκBα at an MOI of 200, 100, 50, and 100, respectively. After 24 hours, cells were treated with TNFα 
(10 ng/ml) or vehicle for 3 days. Cell viability was then assessed by MTS assay. Data is reported as relative cell viability (%) compared to vehicle-treated 
cells (normalized to 100%), which is denoted by the dashed line. Mean ± S.E.M. of 3 independent experiments performed in octuplicate is reported. 
[p < 0.05 (*); p < 0.01 (**); p < 0.001 (***)] (B) BCPAP, SW1736, TPC1, and C643 cells were transduced with either Ad-GFP or Ad-mIκBα at an MOI of 200, 
100, 50, and 100, respectively. After 24 hours, cells were treated with TNFα (10 ng/ml) for 15 min. Nuclear fractions were prepared, and nuclear levels 
of p65 were analyzed by Western blot analysis. PARP was used as a nuclear loading control. (C) SW1736 and TPC1 cells were transduced with either 
Ad-GFP or Ad-mIκBα at an MOI of 100 and 50, respectively. After 24 hours, the cells were serum-starved overnight and then treated with 10 ng/ml 
TNFα for 0, 4, 8, and 16 hours. Whole-cell extracts were harvested, and Western blot analysis was performed to assess levels of cleaved PARP (denoted 
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Page 8 of 13vation by TNFα are two-fold. First, receptor activation
induces formation of complex II, which ultimately trig-
gers mitochondrial release of cytochrome c, and second,
activation of the JNK/SAPK pathway results in down-
stream release of Smac/Diablo into the cytosol to activate
caspase 8. However, under conditions in which NF-κB
signaling is intact, the pro-apoptotic functions of TNFR1
activation are often masked due, in large part, to the sur-
vival functions imparted by NF-κB. Indeed, studies have
shown that abrogation of NF-κB signaling can enhance
TNFα-induced apoptosis [36]. Our results demonstrate
that inhibition of NF-κB signaling promotes TNFα-
induced apoptosis in a subset of cell lines, and this finding
is associated with a sustained activation of JNK in
response to TNFα-treatment in the presence NF-κB inhi-
bition in these cell lines (SW1736, TPC1) (Figure 6). Sus-
tained activation of JNK was not observed in the resistant
cell lines (BCPAP, C643). These data suggest a mecha-
nism by which sensitization of thyroid cancer cell lines to
the combinatorial effects of TNFα-treatment and NF-κB
inhibition requires activation of the JNK pathway that
may, in fact, be cell line and tumor specific. However, the
exact mechanism by which differential activation of JNK
remains unclear and may involve variable regulation of
upstream signaling components. One study showed that
breast cancer cells, which are typically resistant to TNFα-
induced apoptosis, demonstrated enhanced apoptosis
and prolonged activation of JNK when expressing mIκBα
[37]. The authors were able to block induction of apopto-
sis via treatment with an inhibitor of JNK activation. In
our studies, however, treatment with the JNK inhibitor,
SP600125, alone inhibited growth of our thyroid cancer
cell lines (data not shown), likely due to off-target mecha-
nisms associated with the compound, as described by
Bain and colleagues [38]. Another study reported a cell
line-specific, differential activation of JNK following
treatment of two oral squamous cell carcinoma (OSCC)
lines with TRAIL, another ligand known to activate the
TNFR superfamily [39]. While this study did not involve
inhibition of NF-κB, their basic findings were consistent
Figure 6 Sustained Activation of the JNK Pathway Predicts Sensitivity to the Combinatorial Effects of Genetic NF-κB Inhibition and Treat-
ment with TNFα. BCPAP, SW1736, TPC1, and C643 cells were transduced with either Ad-GFP or Ad-mIκBα at an MOI of 200, 100, 50, and 100, respec-
tively. Whole-cell extracts were harvested after 0.5, 1, 2, 4, 8 and 16 hours. Western blot analysis was performed to assess levels of ppJNK 1/2 (Thr-183/
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Page 9 of 13with ours, in that a strong induction of JNK activation
was necessary for OSCC sensitivity to TRAIL-induced
apoptosis.
MMPs belong to a family of endopeptidases, which are
classified based on their specificity for particular extra-
cellular matrix substrates, and are believed to play a criti-
cal role in the acquisition of metastatic potential by
cancer cells by promoting migratory/invasive potential.
MMP regulation is governed by numerous oncogenic
processes, including constitutive activation of NF-κB
[40,41]. In the current study, we have demonstrated dif-
ferential regulation of invasion by NF-κB and evaluated
the expression levels of MMP-2, -9, and -13. These
MMPs are significant in that they are regulated by NF-κB
(MMP-9) and expressed ubiquitously in thyroid cancer
cell lines (MMP-13) [41,42]. Also, expression of both
MMP-2 and MMP-9 is increased in neoplastic thyroid
cell lines when compared to normal thyroid cell lines
[41,42]. Only MMP-9 displayed significantly decreased
transcript levels in response to NF-κB inhibition (Figure
8C). This finding is important, however, given the corre-
lation with MMP-9 expression and poor prognosis in
breast and prostate cancer. No significant regulation of
MMP-2 or MMP-13 was observed. Interestingly, MMP-
13 transcript levels at baseline were at least two-fold
higher in the resistant cell lines (BCPAP, C643) when
compared to transcript levels in sensitive cell lines
(SW1736, TPC1) (Figure 7; Figure 8B). Further studies
will be required to determine the precise mechanisms by
which NF-κB regulates invasion in thyroid cancer cells.
Nonetheless, the insights provided in this study clearly
demonstrate a role for NF-κB in thyroid cancer cell inva-
sion.
Conclusions
In conclusion, our results demonstrate an important and
diverse role for NF-κB signaling in thyroid cancer. Inter-
estingly, these effects are not observed across an entire
panel of thyroid cancer cell lines, and they are not associ-
ated with a particular mutational status or histological
tumor classification. Here, we show distinct roles for NF-
κB signaling in the regulation of thyroid cancer cell prolif-
eration, resistance to TNFα-induced apoptosis, and inva-
sion. Decreased proliferation through blockade of the S-
phase to G2/M transition is observed in response to NF-
κB inhibition. Furthermore, NF-κB likely mediates cancer
cell invasion, at least in part, by driving MMP-9 tran-
scription. Finally, sensitivity to TNFα-induced apoptosis
by inhibition of NF-κB is associated with sustained acti-
vation of the JNK pathway. Taken together, these results
suggest that novel therapeutics targeting NF-κB may be
of clinical utility in the treatment of advanced thyroid
cancer, but this is not likely to be of global use in the
treatment of all thyroid cancers. Downstream markers
may identify which cell lines, and ultimately which




The BCPAP, SW1736, 8505C, TPC1, and C643 thyroid
cancer cell lines were maintained for 10-20 passages at
37°C and 5% CO2 in RPMI 1640 (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) (Hyclone).
The BCPAP and 8505C cell lines were kindly provided by
Dr. M. Santoro (Medical School, University "Federico II"
of Naples, Naples, Italy). The SW1736 and C643 cell lines
were kindly provided by Dr. K. Ain (University of Ken-
tucky), with permission from Dr. N-E Heldin (University
Hospital, S-751 85 Uppsala, Sweden). The TPC1 cell line
was kindly provided by Dr. S. Jhiang (Ohio State Univer-
sity). Cell lines were routinely profiled by Short Tandem
Repeat analysis and are consistent with our previously
published profiles [18].
NF-κB Inhibitors
The NF-κB inhibitors, IKK Inhibitor VII (Calbiochem),
Bay 11-7082 (Calbiochem), and CDDO-Me (kindly pro-
vided by Dr. M. Sporn, Dartmouth Medical School,
Figure 7 Differential Inhibition of Thyroid Cancer Cell Line Inva-
siveness by Blocking NF-κB Signaling. BCPAP, SW1736, TPC1, and 
C643 cells were transduced with either Ad-GFP or Ad-mIκBα at an MOI 
of 200, 100, 50, and 100, respectively. After 24 hours, cells were serum-
starved in RPMI (0.1% FBS) for 6 hours. Cells were then harvested by 
trypsinization and applied to Matrigel-coated transwell chambers in 
RPMI supplemented with 0.1% FBS. Invasion was promoted by the 
presence of RPMI supplemented with 10% FBS in the lower chamber. 
Invaded cells were then fixed, stained with DAPI, and counted, as de-
scribed in Materials and Methods. Data is represented as percent cell 
invasion compared to Ad-GFP control (normalized to 100%), which is 
denoted by the dashed line. Mean ± S.E.M. of 3 independent experi-
ments performed in duplicate is reported. [p < 0.05 (*); p < 0.01 (**); p 
< 0.001 (***)].
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Page 10 of 13Hanover, NH), were dissolved in DMSO at a final concen-
tration of 10 mM.
Adenoviral Transductions
Expression of mIκBα was achieved by adenoviral trans-
duction. Ad-mIκBα and Ad-GFP were kindly provided by
Dr. J. DeGregori (University of Colorado Denver,
Anschutz Medical Campus, Aurora, CO) [25]. For trans-
duction, cells were trypsinized and resuspended in RPMI
supplemented with 1% FBS, transduced in suspension for
1 hour with gentle agitation, and plated at the indicated
cell number in RPMI supplemented with 10% FBS.
Transfections and Reporter Assays
A 3×-κB NF-κB-responsive luciferase reporter comprised
of 3 tandem repeats from the MHC class I enhancer and a
β-galactosidase reporter driven by the actin promoter
(actin β-gal) were kindly provided by Drs. A. Baldwin
(University of North Carolina) and M. Karin (University
of California, San Francisco), respectively. Transfections
were carried out using Lipofectamine 2000 (Invitrogen),
according to manufacturer's protocol. Briefly, thyroid
cancer cells (1.0 × 105) were transduced with either Ad-
GFP (as an appropriate control) or Ad-mIκBα at the indi-
cated MOI and seeded in 24-well plates 24 hours prior to
transfection. DNA (0.8 μg) and Lipofectamine were
diluted in Optimem at a Lipofectamine:DNA ratio of
2.5:1. After 4-6 hours, the media containing the com-
plexes was removed from cells and replaced with fresh
RPMI supplemented 10% FBS. Cells were harvested at 24
hours post-transfection in passive lysis buffer (PLB; Pro-
mega) and subjected to a single freeze-thaw cycle. The
Luciferase Assay System (Promega) and Luminescent β-
galactosidase Detection Kit II (Clontech) were used to
assay luciferase and luminescent β-galactosidase activi-
ties, respectively. Luciferase relative light units (RLU)
were normalized to luminescent β-galactosidase activity
(RLU) to obtain a normalized measure of NF-κB tran-
scriptional activity.
Western Blot Analysis
To prepare whole-cell extracts, cells were washed once
with phosphate-buffered saline (PBS) and harvested in
extraction buffer (EB; 1% Triton X-100, 10 mM Tris, pH
Figure 8 Regulation of MMP-2, -9, and -13 Expression by NF-κB. Quantitative RT-PCR was performed to analyze the regulation of MMP-2 (a), -13 
(b), and -9 (c) transcript levels in cells in response to mIκBα expression. BCPAP, SW1736, TPC1, and C643 cells were transduced with either Ad-GFP or 
Ad-mIκBα at an MOI of 200, 100, 50, and 100, respectively. After 48 hours, total RNA was harvested. Data is represented as picograms target transcript 
corrected for nanograms 18s rRNA (internal standard) (MMP-2) or attagrams target transcript corrected for nanograms 18s rRNA (MMP-9, MMP-13). 
Mean ± S.E.M. of 3 independent experiments performed in duplicate is reported. [p < 0.05 (*); p < 0.01 (**); p < 0.001 (***)].
A B
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Page 11 of 137.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1 mM phe-
nylmethylsulfonyl fluoride, and 2 mM Na3VO4 supple-
mented with 1× complete protease inhibitors (Roche
Diagnostics). Cellular debris was then removed by cen-
trifugation at 13,000 rpm for 10 minutes at 4°C. Nuclear
and cytoplasmic extracts were prepared using the
Nuclear Extract Kit (Active Motif ), according to manu-
facturer's instructions. Extracts (40 μg) were resolved on
10% SDS-PAGE and transferred to Immobilon-P transfer
membranes (Millipore). Membranes were probed with
primary antibodies against PARP (rabbit polyclonal,
AB16661, Millipore), cleaved PARP (mouse monoclonal,
AB3565, Millipore), α-tubulin (mouse monoclonal,
DM1A, Calbiochem), RelA (mouse monoclonal, F-6,
Santa Cruz), IκBα (rabbit polyclonal, FL, Santa Cruz),
ppSAPK/JNK (mouse monoclonal, #9255s, Thr-183/Tyr-
185, Cell Signaling), SAPK/JNK (rabbit polyclonal, #9252,
Cell Signaling), cyclin B1 (rabbit polyclonal, #4138, Cell
Signaling), cyclin A (mouse monoclonal, #4656, Cell Sig-
naling), and p21 (rabbit monoclonal, #2947, Cell Signal-
ing) in blocking buffer (5% nonfat dry milk in 20 mM
Tris, pH 7.4, 138 mM NaCl, 0.1% Tween (TBST)) over-
night at 4°C. Membranes were washed with TBST and
incubated with secondary goat anti-rabbit or goat anti-
mouse horseradish peroxidase-conjugated antibody (GE
Healthcare) for 3 h at room temperature. Immunoreac-
tivity was visualized by enhanced chemiluminescence
detection (Pierce). Blots were stripped and re-probed,
where indicated, using Re-Blot Plus Mild (Millipore).
Automated Cell Counting Assays
For studies with pharmacologic inhibitors of NF-κB, thy-
roid cancer cells (1.5 × 104 - BCPAP, C643, SW1736, and
8505C; 7.5 × 103 - TPC1) were seeded in 6 cm plates. The
following day, cells were treated with either vehicle
(DMSO), IKK Inhibitor VII (1 μM), Bay 11-7082 (1 μM),
or CDDO-Me (0.25 μM). Cells were replenished with
fresh RPMI (10% FBS) supplemented with drug or vehicle
after two days. After a total of five days of treatment, the
media was collected, and adherent cells were washed with
PBS and harvested by trypsinization. Cells were then
combined with the collected media, centrifuged at 1,000
rpm for 5 minutes, and resuspended in 0.5 ml PBS. Viable
cells were then counted using the Vi-CELL Coulter
Counter (Beckman, Inc). For viral transduction studies,
cells (1.5 × 104 - BCPAP, C643, SW1736, and 8505C; 7.5 ×
103 - TPC1) were transduced as described above with
either Ad-GFP or Ad-mIκBα at an MOI of 50 or 200 and
then seeded in 6 cm plates. On the following day, the
media was replaced with fresh RPMI (10% FBS). The
media was again replaced with fresh RPMI (10% FBS) two
days later. Five days post-transduction, media and cells
were collected, and viable cell number was assessed as
described above by ViCell counting.
Cell Cycle Analysis
8505C thyroid cancer cells (7.5 × 105) were transduced as
described above with either Ad-GFP or Ad-mIκBα at an
MOI of 25. Cells were then seeded in 10 cm dishes in
RPMI (10% FBS). After 48 hours, adherent cells were har-
vested by trypsinization and washed with PBS. Cell pel-
lets were resuspended in a saponin/propidium iodide
solution (0.3% saponin, 25 μg/mL propidium iodide, 0.1
mM EDTA, and 10 μg/mL RNase A). Cells were incu-
bated at 4°C for 8 hours, and cell cycle distribution was
determined by flow cytometry using a Beckman Coulter
FC500 at the University of Colorado Cancer Center Flow
Cytometry Core. ModFit LT (Verity Software House) was
used for cell cycle modeling and doublet discrimination.
Cell Viability Assays
Thyroid cancer cells were transduced with either Ad-GFP
(as an appropriate control) or Ad-mIκBα at an MOI suffi-
cient to achieve greater than 90% of NF-κB transcrip-
tional activity, as determined by luciferase assay (BCPAP-
200; SW1736-100; TPC1-50; C643-100). Cells (2,500/well
for TPC1; 5,000/well for BCPAP, SW1736, and C643)
were seeded in octuplicate into 96-well plates in RPMI
supplemented with 10% FBS. Cells were treated the next
day with medium containing 10 ng/ml TNFα (GenScript)
(or vehicle) for three days, and cell viability was assayed
after three days. Cell viability was measured per manufac-
turer's instructions using the CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay (Promega) with an
MRX Microplate Reader (Dynatech Laboratories) and the
Revelation software at an absorbance of 490 nm.
Assessment of Apoptosis
Apoptosis was assessed by Western blot analysis of
cleaved PARP, as described above. For these studies, cells
were serum-starved overnight prior to treatment.
Cleaved PARP is the 89 kD cleavage product of poly
(ADP-ribose) polymerase 1 (PARP1), which serves as a
caspase substrate during the early stages of apoptosis
[43].
Invasion Assays
Thyroid cancer cells were transduced as described above
with either Ad-GFP or Ad-mIκBα at an MOI sufficient to
achieve greater than 90% inhibition of NF-κB transcrip-
tional activity, as determined by luciferase assay (BCPAP-
200; SW1736-100; TPC1-50; C643-100). Twenty-four
hours later, the media was replaced with fresh RPMI
(0.1% FBS). After 6 hours, cells (1.0 × 105) were harvested
and seeded in the upper chambers of Matrigel-coated
transwell chambers (24-well, 8 μM pore size; BD Biosci-
ences) in RPMI (0.1% FBS). Cell invasion was promoted
by the presence of RPMI supplemented with 10% FBS in
the lower chamber. After 24 hours, non-invading cells on
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swab, and invading cells on the lower surface were fixed
with methanol and stained with 3 μg/mL 4',6-diamidino-
2-phenylindole (DAPI; Invitrogen). Cell invasion was
assessed by counting DAPI-stained nuclei in five micro-
scopic fields under 10× magnification using the Meta-
morph software (Molecular Devices) and Nikon
microscope.
Quantitative RT-PCR
Thyroid cancer cells were transduced with either Ad-GFP
(as an appropriate control) or Ad-mIκBα at an MOI suffi-
cient to achieve greater than 90% of NF-κB transcrip-
tional activity, as determined by luciferase assay (BCPAP-
200; SW1736-100; TPC1-50; C643-100). Total RNA was
isolated from the cells after 48 hours using the Perfect-
Pure RNA Cultured Cell Kit (5 Prime) as per the manu-
facturer's protocol. The mRNA levels of MMP-2, -9, and -
13 were measured by real-time quantitative reverse tran-
scription-PCR using ABI PRISM 7700.








Amplification reactions and thermal cycling conditions
were optimized for each primer-probe set and carried out
by the University of Colorado Cancer Center QRT-PCR
Core. A standard curve was generated using the fluores-
cent data from the 10-fold serial dilutions of control
RNA. This was then used to calculate the transcripts lev-
els of MMP-2, -9, and -13 in the RNA samples. Quantities
of MMP-2, -9, and -13 in samples were normalized to the
corresponding 18S rRNA (PE ABI, P/N 4308310).
Statistical Analysis
Statistical significance between groups was determined
using the two-tailed t-test (GraphPad Prism) [p < 0.05 (*);
p < 0.01 (**); p < 0.001 (***)]
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